Intravenous Immunoglobulin (IVIg) Market Size Estimated to Observe Significant Growth by 2026

Noteworthy growth in the incidences of neurological disorders and autoimmune diseases across the globe is projected to help in the expansion of the global intravenous immunoglobulin (IVIG) market, according to a new study published by TMR. The study notes that the market will develop at 8.1% CAGR during forecast period 2018 to 2026. Over the period of past few years, there is notable growth in the older population across major parts of the world. This factor is likely to work as one of the key driver for the growth of the intravenous immunoglobulin (IVIG) market. Apart from this, the market will develop on the back of increased demand for highly dependable and adequate treatment measures, growing incidences of different neurological and hematological disorders, and surge in IVIG usage in off-label indications. In addition to this, the development of advanced technologies for production and purification techniques may play a key role in fueling demand for IVIG in the forthcoming years. Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php? flag=B&rep_id=1930 Home Care: Highly Lucrative End-User Segment Showing Avenues for Rapid Growth The players operating in the intravenous immunoglobulin (IVIG) market are projected to gather prodigious avenues from the home care end-user segment. This growth of the market for of intravenous immunoglobulin (IVIG) is attributable to many factors including shifting patients’ preference for improved care at home, largely in many developed countries. Besides, the IVIG infusion is time consuming as the process of infusion requires a long period of time. Owing to this reason, the patients going through this process prefer the option of home care treatment. This scenario is creating prominent demand opportunities for home care end-user segment of the intravenous immunoglobulin (IVIG) market. Enterprises Focus on the Development of New and Advanced Therapies ADMA Biologics, Inc., Shire plc, CSL Behring LLC, China Biologic Products, Inc., Kedrion S.p.A., Grifols S.A., Octapharma AG, Sanquin Plasma Products B.V., and LFB Biomedicaments S.A. are some of the key players working in the global intravenous immunoglobulin (IVIG) market. The existence of many players indicates that the market competition is highly intense. Thus to sustain in this situation, players in the market are utilizing various strategic moves. Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php? flag=CR&rep_id=1930 Major enterprises in the intravenous immunoglobulin (IVIG) market are increasing their investments in the research and development activities. One of the prime motives of this tactic is the development and launch of new and advanced therapies. Asia Pacific: Prominent Region for Market Growth

Turn static files into dynamic content formats.

Create a flipbook